Study guide
14.1 Contraceptive Efficacy Tiers & Long-Acting Reversible Contraception
AMCB Certified Nurse-Midwife CNM
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Early Pregnancy — Diagnosis, History, Dating & Models of Care
1.1 Signs of Pregnancy, hCG Kinetics & Acceptance of Pregnancy 1.2 Prenatal History, Obstetric Notation & Gestational Dating 1.3 The Initial Prenatal Laboratory Panel 1.4 Prenatal Genetic Screening, Diagnostic Testing & Hereditary Risk 1.5 Models of Prenatal Care, Birth-Setting Counseling & Community Referral
2 Chapter 2: Ongoing Prenatal Assessment, Nutrition & Common Discomforts
2.1 Prenatal Visit Cadence, Milestone Screening & Fundal Height 2.2 Leopold Maneuvers, Fetal Heart Auscultation & Antepartum Surveillance 2.3 Clinical Pelvimetry & Assessment of the Bony Pelvis 2.4 Maternal Nutrition, Weight Gain & Immunization in Pregnancy 2.5 Nausea, Vomiting & Gastrointestinal Discomforts of Pregnancy 2.6 Musculoskeletal, Vascular & Neurologic Discomforts of Pregnancy
3 Chapter 3: Hypertensive, Endocrine & Hematologic Complications of Pregnancy
3.1 Classification & Diagnosis of Hypertensive Disorders of Pregnancy 3.2 Acute Severe Hypertension, Magnesium Sulfate & Eclampsia 3.3 Delivery Timing, Aspirin Prophylaxis & Postpartum Hypertension 3.4 Gestational Diabetes: Pathophysiology, Screening & Diagnosis 3.5 Glycemic Management, Fetal Surveillance & Delivery Timing in Gestational Diabetes 3.6 Thyroid Disorders & Anemia in Pregnancy
4 Chapter 4: Bleeding, Amniotic Fluid Disorders, Preterm Birth & Perinatal Loss
4.1 First-Trimester Bleeding, Early Pregnancy Loss & Gestational Trophoblastic Disease 4.2 Ectopic Pregnancy: Diagnosis & Management 4.3 Third-Trimester Bleeding & Amniotic Fluid Volume Disorders 4.4 Preterm Labor & Preterm Prelabor Rupture of Membranes 4.5 Intrauterine Fetal Demise, Stillbirth & Bereavement Care
5 Chapter 5: Normal Labor, Birth & Intrapartum Fetal Surveillance
5.1 Onset of Labor, True Versus False Labor & Nutrition in Labor 5.2 The First and Second Stages of Labor 5.3 Cardinal Movements, Third & Fourth Stages of Labor 5.4 Cord Clamping, Cord Blood, Cord Gases & Placental Examination 5.5 Fetal Oxygenation, Intermittent Auscultation & Uterine Activity Monitoring 5.6 Electronic Fetal Monitoring Parameters & the NICHD Categories 5.7 Intrauterine Resuscitation, Scalp Electrode & Amnioinfusion
6 Chapter 6: Labor Support, Analgesia, Induction & Augmentation
6.1 The Midwifery Model, Continuous Labor Support & Non-Pharmacologic Comfort 6.2 Water Immersion, Waterbirth & Non-Supine Birth Positions 6.3 Systemic, Neuraxial & Regional Analgesia in Labor 6.4 Indications & Timing for Induction of Labor 6.5 The Bishop Score & Cervical Ripening Methods 6.6 Oxytocin Titration, Tachysystole Management & Amniotomy
7 Chapter 7: Intrapartum Emergencies, Malpresentation & Perineal Repair
7.1 Shoulder Dystocia: Recognition & the HELPERR Protocol 7.2 Dystocia Complications, Umbilical Cord Prolapse & Intraamniotic Infection 7.3 Malposition, Manual Rotation, Breech, Face Presentation & Nuchal Cord 7.4 Perineal Anatomy & Classification of Obstetric Lacerations 7.5 Episiotomy & Surgical Perineal Repair 7.6 TOLAC, VBAC & Uterine Rupture
8 Chapter 8: The Normal Puerperium, Postpartum Assessment & Lactation
8.1 Puerperal Physiology, Uterine Involution & Lochia 8.2 The BUBBLE-HE Postpartum Assessment 8.3 Bladder, Bowel & Perineal Care and the Postpartum Care Continuum 8.4 Lactation Neuroendocrinology & the Stages of Lactogenesis 8.5 LATCH Assessment, Latch Biomechanics & Adequate Intake 8.6 Lactation Complications, Medication Safety & Contraindications
9 Chapter 9: Postpartum Contraception, Family Planning & Hemorrhage
9.1 Return of Fertility, Lactational Amenorrhea & US MEC in the Puerperium 9.2 Postpartum Hormonal Contraception & Intrauterine Devices 9.3 Barrier & Permanent Contraception, Postpartum Sexuality & Family Support 9.4 Postpartum Hemorrhage: Definition, Shock Recognition & Quantitative Blood Loss 9.5 The Four Ts: Etiology of Postpartum Hemorrhage 9.6 Hemorrhage Resuscitation, Uterotonics, TXA & Surgical Escalation
10 Chapter 10: Puerperal Infection, Thromboembolism, Cesarean Recovery & Perinatal Mental Health
10.1 Puerperal Endometritis & Septic Pelvic Thrombophlebitis 10.2 Puerperal Wound Infection, Mastitis & Breast Abscess 10.3 Postpartum Venous Thromboembolism 10.4 Post-Cesarean Recovery: Inpatient Care & Care After Discharge 10.5 Postpartum Blues, Depression & EPDS Screening 10.6 Treating Postpartum Depression, Anxiety, OCD & Psychosis
11 Chapter 11: Neonatal Transition, Resuscitation & the Newborn Examination
11.1 Fetal-to-Neonatal Transition & Circulatory Remodeling 11.2 APGAR Scoring & the NRP Initial Steps 11.3 Positive Pressure Ventilation, MR. SOPA & Advanced Resuscitation 11.4 Newborn Vital Signs, Anthropometrics & the Ballard Score 11.5 Cranial Assessment & Head-to-Chest Examination 11.6 Genitourinary & Musculoskeletal Examination and Primitive Reflexes
12 Chapter 12: Newborn Prophylaxis, Screening, Common Disorders & Care Through 28 Days
12.1 Standard Neonatal Prophylaxis: Vitamin K, Eye Ointment & Hepatitis B 12.2 Universal Newborn Screening: Hearing, CCHD & Dried Blood Spot 12.3 Neonatal Hypoglycemia, Thermoregulation & the Infant of a Diabetic Mother 12.4 Neonatal Hyperbilirubinemia & Phototherapy 12.5 Infant Feeding Education, Circumcision Counseling & Care Through 28 Days
13 Chapter 13: Well-Woman Preventive Care, Cancer Screening & Immunization
13.1 The Well-Woman Visit & Cervical Cancer Screening 13.2 ASCCP Risk-Based Management & Breast Cancer Screening 13.3 Colorectal Cancer & Osteoporosis Screening 13.4 Adult Immunization & Environmental and Occupational Exposure Screening
14 Chapter 14: Contraception, Abortion Care & Fertility Evaluation
14.1 Contraceptive Efficacy Tiers & Long-Acting Reversible Contraception 14.2 Combined Hormonal Contraception 14.3 Progestin-Only Methods & Emergency Contraception 14.4 Abortion Care: Options Counseling, Medication Abortion & Follow-Up 14.5 Initial Infertility Evaluation & Gynecologic Imaging Referral
15 Chapter 15: Benign Gynecologic Conditions, Pelvic Floor & Menstrual Disorders
15.1 Endometriosis & Adenomyosis 15.2 Pelvic Organ Prolapse & Urinary Incontinence 15.3 Adnexal Masses, Malignancy Red Flags & Vulvar Disease 15.4 The Normal Menstrual Cycle & Anticipatory Guidance 15.5 The FIGO PALM-COEIN Classification of Abnormal Uterine Bleeding 15.6 Evaluating Abnormal Uterine Bleeding & the Amenorrhea Workup 15.7 Polycystic Ovary Syndrome
16 Chapter 16: Vaginitis, Sexually Transmitted Infections, Sexual Health & Menopause
16.1 Differential Diagnosis of Vaginitis & Bacterial Vaginosis 16.2 Candidiasis, Trichomoniasis, Chlamydia & Gonorrhea 16.3 Pelvic Inflammatory Disease 16.4 Genital Herpes, Syphilis & Anogenital Warts 16.5 Sexual Health Assessment, Sexual Function & Care After Sexual Assault 16.6 Reproductive Aging, Menopause Definitions & Clinical Manifestations 16.7 Menopausal Hormone Therapy 16.8 Non-Hormonal Therapies & Postmenopausal Osteoporosis
17 Chapter 17: Primary Care — Chronic Disease & Common Acute Conditions
17.1 Midwifery Primary Care Scope & Hypertension Management 17.2 Antihypertensive Pharmacotherapy & Hyperlipidemia 17.3 Type 2 Diabetes & Thyroid Disease in Primary Care 17.4 Respiratory Infections, Asthma & Urinary Tract Infection 17.5 Gastrointestinal & Dermatologic Conditions 17.6 Mental Health Screening & Substance Use Disorders 17.7 Intimate Partner Violence, Reproductive Coercion & Human Trafficking
18 Chapter 18: Midwifery Scope of Practice, Ethics, Collaboration & Health Equity
18.1 Regulatory Foundation of Practice & the Midwifery Model of Care 18.2 Bioethics, Informed Refusal & Collaborative Practice 18.3 Maternal Health Disparities, Structural Racism & Inclusive Care
14.1 Contraceptive Efficacy Tiers & Long-Acting Reversible Contraception
Key Takeaways Explain This Topic AI
The etonogestrel implant has a typical-use failure rate of 0.05 percent, lower than surgical sterilization, and is FDA approved for 3 years with evidence supporting 5.
Levonorgestrel IUDs reduce menstrual blood loss by 70 to 90 percent and are first-line therapy for idiopathic heavy menstrual bleeding.
The copper IUD works by a sterile inflammatory reaction and direct spermicidal copper toxicity, is FDA approved for 10 years with data through 12, and increases menstrual loss and dysmenorrhea.
IUD insertion requires a sounded uterine depth of 6 to 10 cm, and the device should not be placed if depth is under 6 cm.
IUD-associated pelvic inflammatory disease risk is elevated only during the first 20 days after insertion, after which it returns to background.
Last updated: September 2026
Family planning and contraceptive counseling are fundamental dimensions of comprehensive well-woman care. Grounded in autonomy, bodily integrity, and shared clinical decision-making, the certified nurse-midwife partners with patients to align individual reproductive life goals with medical safety, lifestyle preferences, and efficacy profiles. Understanding the physiological mechanisms, adverse effect profiles, anticipatory guidance, and medical safety frameworks defined by the Centers for Disease Control and Prevention (CDC) Medical Eligibility Criteria for Contraceptive Use (US MEC) and Selected Practice Recommendations (US SPR) is vital for safe clinical practice and AMCB certification.
The Contraceptive Efficacy Spectrum & Tier Architecture
Contraceptive methods are categorized into three distinct tiers based on typical-use and perfect-use annual failure rates (percentage of individuals experiencing an unintended pregnancy during the first year of use). Contraceptive efficacy is fundamentally governed by the degree to which the method depends on continuous, correct user compliance. Contraceptive Efficacy Hierarchy (Typical-Use Failure Rates)
- ├── Tier 1: Long-Acting Reversible Contraception (LARC) & Permanent (<1%)
- │ ├── Subdermal Etonogestrel Implant (Nexplanon) ──> 0.05%
- │ ├── Levonorgestrel Intrauterine Devices (LNG-IUD) ──> 0.1% - 0.2%
- │ ├── Copper Intrauterine Device (ParaGard) ──> 0.6% - 0.8%
- │ ├── Vasectomy ──> 0.15% (Requires 3-month post-procedure semen confirmation)
- │ └── Bilateral Tubal Ligation / Salpingectomy ──> 0.5%
- ├── Tier 2: Hormonal & User-Adherence Dependent Methods (4% - 7%)
- │ ├── Depot Medroxyprogesterone Acetate (DMPA Injection) ──> 4%
- │ ├── Combined Oral Contraceptive Pills (COCs) ──> 7%
- │ ├── Progestin-Only Pills (POPs) ──> 7%
- │ ├── Transdermal Contraceptive Patch ──> 7%
- │ └── Contraceptive Vaginal Rings ──> 7%
- └── Tier 3: Coitus-Dependent & Barrier Methods (13% - 28%)
- ├── Male Latex / Polyurethane Condoms ──> 13% (Only method offering STI protection)
- ├── Diaphragm with Spermicide ──> 17%
- ├── Fertility Awareness-Based Methods (FABMs) ──> 15% - 24%
- ├── Coitus Interruptus (Withdrawal) ──> 20%
- ├── Internal (Female) Condoms ──> 21%
- ├── Contraceptive Sponge ──> 14% (nulliparous) / 27% (parous)
- └── Spermicides Alone (Nonoxynol-9) ──> 28%
- The CDC Medical Eligibility Criteria (US MEC) System
The CDC US MEC provides evidence-based guidance on the safety of contraceptive methods in the presence of specific medical conditions:
Category 1: A condition for which there is no restriction for the use of the contraceptive method.
Category 2: A condition where the advantages of using the method generally outweigh the theoretical or proven risks (safe to use; routine clinical follow-up).
Category 3: A condition where the theoretical or proven risks usually outweigh the advantages of using the method (use is not recommended unless other more appropriate methods are unavailable or unacceptable; requires expert clinical consultation).
Category 4: A condition that represents an unacceptable health risk if the contraceptive method is used ( strictly contraindicated ; absolute medical prohibition).
Long-Acting Reversible Contraception (LARC)
Long-acting reversible contraceptives (LARCs) include the subdermal etonogestrel implant and intrauterine devices (IUDs). Because they require no user intervention following placement, their typical-use failure rates are identical to their perfect-use failure rates (<1% annually), representing the most effective reversible methods available.
1. Etonogestrel Subdermal Implant (Nexplanon)
Device Characteristics: A single 4 cm × 2 mm ethylene vinyl acetate rod preloaded in a sterile disposable applicator, containing 68 mg of etonogestrel (a potent third-generation progestin).
Mechanism of Action: Releases ~60 to 70 mcg/day initially, slowly declining to ~25 to 30 mcg/day by year 3. The primary mechanism is sustained suppression of ovulation by suppressing the mid-cycle luteinizing hormone (LH) surge via negative feedback on the hypothalamic-pituitary-ovarian (HPO) axis. Secondary mechanisms include thickening of cervical mucus (creating a barrier to sperm penetration within 24 hours of placement) and endometrial thinning/atrophy .
Efficacy & Duration: Typical failure rate is 0.05% (higher efficacy than surgical sterilization). FDA approved for 3 years , but extensive multicenter clinical trials and ACOG/CDC practice bulletins support high efficacy through 5 years of continuous use.
Anticipatory Bleeding Guidance & Management:
Unscheduled, irregular bleeding is the most common side effect and the leading cause of premature discontinuation (~15%). Bleeding changes do not reflect decreased efficacy or structural pathology.
Patterns include: amenorrhea (~20%), infrequent bleeding (~30%), frequent bleeding (~10%), or prolonged spotting (~15%–20%). The bleeding pattern experienced in the first 3 months typically predicts future bleeding patterns.
First-Line Medical Therapy for Troublesome Bleeding: A 5- to 7-day course of scheduled nonsteroidal anti-inflammatory drugs ( Ibuprofen 800 mg PO TID with meals or Mefenamic acid 500 mg PO TID ) to suppress endometrial prostaglandin synthesis and microvascular breakdown. Alternatively, a 10- to 20-day course of low-dose combined oral contraceptives (or oral estradiol 1 to 2 mg daily) can stabilize the fragile endometrial vascular bed.
Insertion Anatomy: Inserted subdermally in the inner aspect of the non-dominant upper arm, 8 to 10 cm proximal to the medial epicondyle of the humerus, overlying the groove between the biceps and triceps muscles, avoiding the sulcus to prevent injury to the ulnar nerve and brachial vessels.
2. Levonorgestrel Intrauterine Devices (LNG-IUDs)
Formulations:
Mirena: 52 mg LNG (initial release 20 mcg/day); FDA approved for 8 years ; approved for contraception and heavy menstrual bleeding.
Liletta: 52 mg LNG (initial release 20 mcg/day); FDA approved for 8 years .
Kyleena: 19.5 mg LNG (initial release 17.5 mcg/day); FDA approved for 5 years ; smaller frame and narrower inserter barrel.
Skyla: 13.5 mg LNG (initial release 14 mcg/day); FDA approved for 3 years .
Mechanism of Action: High local intrauterine concentration of levonorgestrel induces profound endometrial decidualization and glandular atrophy , rendering the endometrium unreceptive to blastocyst implantation. It thickens cervical mucus to impede sperm ascension and impairs uterotubal sperm motility. Importantly, most cycles remain ovulatory (especially after the first year), preserving endogenous ovarian estradiol production.
Clinical Benefits: Produces a 70% to 90% reduction in menstrual blood loss ; first-line therapy for idiopathic heavy menstrual bleeding and adenomyosis; significant alleviation of dysmenorrhea and endometriosis pain. Amenorrhea rates reach 20% to 50% by 12 months with 52 mg devices.
Insertion Protocol & Sounding: Perform bimanual examination to establish uterine position and axis. Apply antiseptic solution to cervix. Place a single-tooth tenaculum on the anterior lip (or posterior lip if retroverted) and exert gentle axial counter-traction to straighten the cervico-uterine angle. Sound the uterine cavity with a sterile sound: normal depth is 6 to 10 cm ( do NOT insert if sounded depth is <6 cm ). Advance the loaded inserter to fundal depth, deploy the arms, release the device, and trim strings to 3 to 4 cm from the external os.
Complications & Infection Timing: Uterine perforation occurs in approximately 1 per 1,000 insertions (higher in lactating women due to myometrial softness). Expulsion occurs in 2% to 10% (highest in the first year and following immediate post-abortion or postpartum placement). The risk of pelvic inflammatory disease (PID) is elevated ONLY during the first 20 days following insertion , resulting from the introduction of cervical microflora into the uterine cavity during insertion; after 20 days, the background PID risk returns to that of the general population.
3. Copper Intrauterine Device (ParaGard T 380A)
Device Characteristics: Polyethylene T-frame wound with 380 mm² of pure copper wire and copper sleeves; completely non-hormonal.
Mechanism of Action: Continuous dissolution of copper ions into the endometrial cavity incites a sterile local inflammatory reaction characterized by foreign-body leukocytic, macrophage, and cytokine infiltration. Copper ions are directly cytotoxic and spermicidal , profoundly inhibiting sperm motility, viability, capacitation, and the acrosome reaction, preventing fertilization.
Efficacy & Duration: Failure rate is 0.6% to 0.8% . FDA approved for 10 years , with extensive clinical trial data demonstrating high efficacy through 12 years .
Clinical Profile & Side Effects: Excellent choice for individuals seeking non-hormonal contraception or those with absolute contraindications to estrogens and progestins (e.g., active breast cancer). Expected adverse effects include an increase in menstrual blood loss (30% to 50%) and dysmenorrhea , most prominent in the first 3 to 6 months. Prophylactic scheduled NSAIDs during menses provide effective symptom relief.